Expansion of the existing French newborn screening programme to include MCADD is effective in reducing MCADD mortality and morbidity and is cost-effective, particularly if the expansion to MCADD screening (which requires the introduction of tandem mass spectrometry [MS/MS] technology) is coupled with a shift in technology (to MS/MS) for the screening of phenylketonuria (PKU).
HAS recommends to expand newborn screening to MCADD in the general population in France. This screening necessarily implies the use of the MS/MS. Corollary, for efficiency reasons, HAS recommends at the same time a shift to the MS/MS technology for the screening of PKU.